Data from preclinical studies suggest that adding rituximab to an anti‐CD19 pyrrolobenzodiazepine ADC prolongs tumor control, providing a rationale for combining loncastuximab tesirine with rituximab as a treatment for R/R DLBCL.75 This evidence concerns the gene CD19 and neoplasm.